Credelio Plus

lotilaner / milbemycin oxime

Table of contents


On 8 December 2022, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Credelio Plus. The marketing authorisation holder for this veterinary medicinal product is Elanco GmbH.

Credelio Plus is currently authorised as chewable tablets for use in dogs. The variation concerns the addition of a new therapeutic indication for the treatment of demodicosis (caused by Demodex canis).

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

1 Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Key facts

Credelio Plus
Agency product number
International non-proprietary name (INN) or common name
  • lotilaner / milbemycin oxime
Active substance
  • lotilaner
  • milbemycin oxime
Date opinion adopted
Company name
Elanco GmbH
Application type

Related content

How useful was this page?

Add your rating